Trial Profile
A Phase I, Multi-arm, Dose Escalation Study of Brivanib Alaninate Combined With Several Chemotherapy Regimens in Subjects With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jun 2015
Price :
$35
*
At a glance
- Drugs Brivanib alaninate (Primary) ; Capecitabine; Docetaxel; Doxorubicin; Ixabepilone; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 02 Jun 2015 Status changed from active, no longer recruiting to completed as ClinicalTrials.gov record.
- 20 May 2015 Planned End Date changed from 1 Mar 2015 to 1 May 2015, according to ClinicalTrials.gov record.
- 20 May 2015 Planned primary completion date changed from 1 Mar 2015 to 1 May 2015, according to ClinicalTrials.gov record.